Classes
DEA Class; Rx
Common Brand Names; Hycofenix
- Antitussives, Narcotic Combos
Description
Hydrocodone: Antitussive; narcotic agonist analgesic
Pseudoephedrine: Decongestant; alpha adrenergic agonist
Guaifenesin: Reduces viscosity of secretions by increasing amount of respiratory tract fluid
Indications
Contraindications
Documented hypersensitivity
Patients receiving MAOI therapy or within 14 days of stopping such therapy
Narrow angle glaucoma
Urinary retention
Severe hypertension
Severe coronary artery disease
Adverse Effects
Hydrocodone
Respiratory depression
Drug dependence
Increased intracranial pressure
Decreased mental alertness with impaired mental and/or physical abilities
Paralytic ileus
Pseudoephedrine
CNS effects (eg, insomnia, dizziness, weakness, tremor, or convulsions)
Cardiovascular system effects (eg, arrhythmias, or increased blood pressure), cardiovascular collapse with accompanying hypotension
Warnings
Hydrocodone produces dose-related respiratory depression by directly acting on brain stem respiratory centers
Hydrocodone can produce drug dependence and tolerance may develop upon repeated administration; prescribe with same degree of caution as use of other opioid drugs
Respiratory depression effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure
Hydrocodone may produce marked drowsiness and impair mental and physical abilities required for hazardous activities (eg, driving); concurrent use with alcohol or other CNS depressants should be avoided
Caution in patients with acute abdominal conditions; hydrocodone may obscure the diagnosis or clinical course of acute abdominal illness
Concurrent use of anticholinergics with hydrocodone may cause paralytic ileus
Use of MAOIs or TCAs with hydrocodone may increase the effect of either the antidepressant or hydrocodone; do not use with MAOIs or within 14 days of stopping an MAOI
Pseudoephedrine can produce cardiovascular and CNS effects in some patients (eg, insomnia, dizziness, weakness, tremor, or arrhythmias); CNS stimulation with convulsions or cardiovascular collapse with accompanying hypotension has also been reported
Do not for persistent or chronic cough (eg, associated with smoking, asthma, chronic bronchitis, or emphysema), or where cough is accompanied by excessive phlegm
Measure dose with accurate milliliter measuring device to avoid overdose
Caution with diabetes, thyroid disease, Addison disease, prostatic hypertrophy, urethral stricture, and asthma
Caution with severe renal or hepatic impairment
Pregnancy and Lactation
Pregnancy category: C
Caution; hydrocodone and pseudoephedrine are known to be excreted in human milk; no studies have been performed to determine if guaifenesin is excreted into breastmilk
Maximum Dosage
Adults
10 mL PO q4-6hr; not to exceed 4 doses (40 mL) per 24 hr
Pediatric
<18 years: Safety and efficacy not established
Use of hydrocodone in children aged <6 years is associated with fatal respiratory depression
How supplied
hydrocodone/pseudoephedrine/gauifenesin
oral solution: Schedule III
- (2.5mg/30mg/200mg)/5mL